Fig. 4From: Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVEProportion of patients with overall NEDA during the first or second year of natalizumab treatment. Only patients with no missing data at the time of the assessment were included. NEDA = no evidence of disease activityBack to article page